Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential of [fam-] trastuzumab deruxtecan (DS-8201) in HER2-positive breast cancer.

In October 2019, the FDA granted a priority review to [fam-] trastuzumab deruxtecan for the treatment of patients with metastatic HER2-positive breast cancer. If the agent is approved, it could be sequenced as third-line therapy where current options are relatively toxic, says Vidal.  

Notably, this drug also appears to have activity in patients with low HER2 expression. As such, it could show activity in patients with triple negative breast cancer, concludes Vidal.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

HER2+ Breast Cancer

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

University of Tennessee West Cancer Center

Cancer Centers

Partner

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer. 
 

Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer